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A macrocyclic rcnin inhibitor was designed using molecular modeling and a model of human rcnin. The synthcsircd molecule displayed poor binding 
affinity. To investigate the reasons for the observed inactivity, the structure of the compound has been studied by NMR speclroscopy and distance 
geometry. Structural constraints for distance geometry calculations were derived from nuclear Overhauscr cffccts and homonuclcar and hetcronu- 
clear three bond coupling constants, Homonuclear coupling constants were measured irectly from the rcsolution-enhanccd proton spectra nd 
heteronuclearcouplingconstants were measured from the natural abundance “N-and ‘“C-cditcd TOCSY cxperimcnts, One4 angle wasdctcrmined 
uniquely by this method and two were reduced to two possible values each. By using a smtistical analysis of400 structun!! generated with distance 
geometry, two families of structures were found to be consistent with the NMR data. The solution structures o derived were different from the 
originally dcsigncd structure, including an internal hydrogen bond. This provides a possible explanation for the lack of effcctivcncss of this 
compound, 
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1. INTRODUCT’[ON 
Rational, de novo design of drugs is an on-going 
objective in many pharmaceutical nd academic labora- 
tories [I]. In pursuit of this goal, effective use of com- 
puter-aided rug design can guide synthetic efforts, re- 
sulting in more efficient discovery of therapeutic andi- 
dates. Recent technological advances in macromolecu- 
lar crystallography, NMR spectroscopy and computa- 
tional efficiency have begun to provide the tools neces- 
sary to apply this methodology to pharmaceutically rel- 
evant problems. Experimental verification of modeled 
structures is an important feedback mechanism in the 
development of this approach. In this report, we de- 
scribe molecular modeling studies involving a human 
renin enzyme model [2] leading to the design of a con- 
formationally constrained renin inhibitor (Scheme I), 
Abbreviurions: ROE%‘, rotating frame nuclear Overhauser spcctros- 
copy; COSY, corrclatcd spectroscopy; TOCSY, total correlated spec- 
troscopy; AMPMA, ,ncru-di(aminomethyI)benzcnc; BNMA, his-[( I- 
naphthyl)mcthyl]acctic acid; BOC, N-r-butyloxycarbonyl; DCC, 1.3- 
dicyclohexylcarbodiimide; HOBT. I-hydroxybenzotriazole hydrate, 
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2716. 
its synthesis, biological evaluation and subsequent 
structural analysis. In the structural analysis, a methcd 
for measuring heteronuclear coupling constants at natu- 
ral abundance [3] is applied to this compound. The 
combined use of homonuclear 3JNH,Ho and heteFOnu- 
clear ‘JNucs and sJw.N coupling constants has mini- 
mized the ambiguities that arise from the periodic na- 
ture of the Karplus relationship [4] and has provided 
valuable constraints that arc used in conjunction with 
NOE distances in distance geometry calculations. 
AMPMA 
Scheme I. 
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2. EXPERIMENTAL 
The synthesis of the cyclic peptidomimctic is outlined in Scheme 2. 
Compound 1, mono-carbobunryloxy-rn-xylenediamine, AMPMA-Z. 
[S] was isolated from the reaction of nr-xylencdiamine with ben- 
zyloxycarbony: .(oxy)succinimide. This material was coupled IO BOC- 
Lcu using DCC-HOBT, follo*zed by deprotection with anhydrous 
HCI gas in dichloromethane, and the isolation of 3 as the hydrochlo- 
ride. Following neutralization of 3 with tricthylamine in dichloro- 
methane, BOC-Sta [6] was coupled to 3 using DCC-HOBT to give 4. 
The deprotection of 4 gave 5, which was coupled to BOO(y-bcn- 
zyl)Glu, aiving product 6. The y-benzyl ester and carbobcnzyloxy 
proteztinp groups were then simultaneously removed by catalytic hy- 
drogenation which gave 7. A 1% solution of 7 in DMF was cyclized 
to 8 in 71% yield with diphenylphosphorylazide by the applicntion of 
a procedure by Brady et al. [7]. Removal of the BOC group from 8 
with (5O:SO) TFA/dichloromethane, followed by the DCC-HOBT cou- 
pling of BNMA [S] gave the product 10. Further purification was 
;rccomyli+red hy chromatography on silica gel. eluted with chloro- 
form/methanol (95:5). 
Homonuclcar and hetcronuclear NMR experiments were carried 
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Table I 
Selected NMR data for the cyctie pcptidomimetic in DMSO-d6? 
Residue Chemical shifts ~J~ls., Ja. c" J . .  s ~ ,rib'/-42 ~ 
GILa ~t-4.22 7.g Nfl 1.0. Ne, 2.3 a 2.5 -7.4 
,a.I.64, 1.64 /~a -2.5. r"  3.0 ,a -I.0 
),-2.03, 2,03 g8 - 3.0, ~'~ - 4.0 
NH.8,32 ~r ~.o. ~r 2.0 
#r -4,0 
Sta 0~-2.18, 21,8 9,5 N~ 0.7. lsl~ 2.0 ~ -5,0 ¢ -7,1 
fl-3.88 dly -3,0, d~'?. 3,0 d;' -5.0 ~ 
y-3.85 ~8 -1,5, HOe,, 3.0 ), 2.5 
&1.37, 1,27 fla -1,0 
e.l.58 
~'-0,92, 0,83 
OH-4,90 
NH-7,77 
Lea ~-4.18 6,9 Nfl 1.5, N~t 2,0 f1-5,8 -45,1 
fl-1.47, 1,47 fl~t -3,0, aft -4.0 ct 0,0 
y-1.67 yfl -2,5 
~-0,89, 0,85 
NH.8,05 
AMPMA y-7.08 o: 7,6 N~ 2.5 ~t 1.5 -2,8 
c~.7,20 ~' 4,6 Nel 2,0 ,'.' 1.3 -6.1 
e-4.55, 3,99 6 7,6 el 2,0 
e2.7.09 e' 4,6 e' 0,5 
~..4,46, 4,46 
rtN H.7.92 
eNH-8.46 
~Chernical shifts relative to DMSO-d5 = 2.50 ppm, coupling constants in Hz. 
b Pairs of Greek characters rel'er to proton and carbon, respectively, nomenclature as in Scheme I. N indicates the amidc proton, 
Greek character refers to a proton as in the Scheme, Coupling is to the amicle nitrogen 2 to 4 bonds away. 
'~Amide proton dependence in ppb/K between the 280 and 300K, 
The -5,0 Hz coupling constants observed for both the fl protons possibly due to the nonpeptide slructure of the Sta residue. 
out with 15 mg and 50 mg peptidomimetic, respectively, in 0.5 ml of 
dimethylsulfoxide-d6 at 300K, Two-din~ensional double quantum fil- 
tered COSY [9] and ROESY [10] data (512 t l blocks of 2048 t2 data 
points) were acquired on a Bruker AMXS00, For the ROESY data. 
a 4 kHz continuous wave spin-lock fi~.'ld was applied daring the 250 
ms mixing time at the transmitter frequency, The temperature d pend- 
ence of the proton spectrum was determined by acquiring spectra t 
280K, 290K and 300K. Homonuclear coupling constants were meas- 
tared directly from spectra that were resolution enhanced by applica- 
tion of a gaassian function (GB=0.5. LB=-5) to the free induction 
decay prior to Fotarier transformation. Heteronuclear coupling con- 
stants were measured from ~SN-edited and t~C-edited TOCSY spectra 
as described previously for peptides [3] and isotopically enriched pro- 
teins [I 1]. To allow meastarement at natural isotopic abundance, a 
BIRD type hetcronuclear editing pulse was incorporated to select 
protons attached to t~C or 'SN nuclei followed by a conventional 
TOCSY pulse sequence (s¢¢ Fig. !). 
2,3. Molecular modeliag 
The peptidomimetic was designed using Sybyi molecular modeling 
software [12] and a previously described model for human renin [2], 
Distance geometry calculations were carried out using DGEOM [13] 
and the cluster analysis oftware, Compare, as previously described 
[14]. Statistical Analysis Software (SAS) [15] was used to analyze the 
distance geometry structures. 
Energy minimizations and molecular dynamics calculations were 
carried out without electrostatic potentials using the Tripos force field 
in Sybyl [12]. Molecular dynamics calculations were run in the gas 
phase using a Boltzn~ann ~,eighted starting velocity with gradual heat- 
ing for 4.5 ps followed by 20 ps at 300 K. In the. dynamics runs the 
angles were restrained to a designated value with a force constant 
of 0.01 and interproton distances restrained with a tbrc¢ constant of 
I0 and a functional power of 2. 
3. RESULTS AND DISCUSSION 
Molecular modeling studies led to tile design of an 
inhibitor which was sterically and electrostatically com. 
patible with the enzyme binding site. After synthesis and 
biological testing, the inhibitor proved to have very low 
binding affinity for renin (26% inhibition of renin at l 
/~M) [16]. In an attempt to explain the failure of the 
modeling studies, heteronuclear and proton NMR stud- 
ies, coupled with distance geometry and structural anal- 
yses were undertaken to explore the eonformational 
properties of the cyclic peptidomimetic n solution. 
The site-specific proton assignments were obtained 
using standard two-dimensional techniques; the 
AMPMA methylene protons were assigned stereospeei- 
fically based on "~JNH.H-" and NOE data. The chemical 
99 
Volume 302. number I 
X 
IH 
FEBS LETTERS 
Y 
May 1992 
c 
0 
B 
I, ., I l ,I.., ,, .I,., 
756 74a 728 708 4Ai; 
a 
LWJ 1 Irn 
'J(Hkp) . 
1400 ‘m 
-I 
tD 0 Glli 
, 
-m 
-1900 
b Sta 
640 
Hz 
8510 
i 
8570 
0 I 
-rT’J,x, m , i , . , , , , , , , , , J 
5 675 64s 615 Hz 
Volume 302, number 1 FEBS LETTERS May 1992 
Table II Table I11 
Evaluation of conformational families of the cyclic peptioomimetic Intcrprolon upper bound distances derived from ROESY data for the 
Peptidomimetic n DMSO-d6”. 
AMPHA NH6 Leu Ha 2.5 Sta HjI Sta Ha 4.0 
AMP H&S 3.0 Sta H6 4.0 
AMP HER 3.5 Glu Hy 4.0 
Leu H/3 4.0 
AMP Hy 3.0 Sta OH Sta Ha 4S 
Leu NH 3.5 Sta H/8 2.5 
Sta Hy 4.0 Sta Hb 4.0 
Sta H6 4.0 
Run No. 
Criteria” Starting 4, angle (degrees) 
I 2 3 Glu sta Leu 
AMPHA NHo AMP HaR 3.0 
AMP HaS 3.5 Sta Hy Sta Ha 4.0 
Glu Hy 2.5 Sta HE 3.0 
AMP Hy 2.5 Sta H6 3.0 
Sta Hpl 4.0 Sta HC; 4.2 
Glu HP 4.0 
Sta Ha 4.0 Sta Ha Sta M6 4.0 
AMPMA Hy Glu H/3 4.0 LeuNH Leu Ha 3.0 
Glu Hy 4.0 Sta Hfi 4.0 
AMP HaR 3.0 Sta Ha 2.5 
AMP HaS 3.5 Leu Hy 3.0 
AMP H& 3.0 Leu I$5 3.0 
AMPHaR 3.5 
Leu Ha 3.5 Leu Ha Leu Hy 3.5 
Leu H/V 3.5 
AMPMA H&2 AMP HsS 3.5 Leu H6 4.0 
AMPHaR 2.5 Leu NH Sta OH 4.0 
AMPMA Hy2 AMP HaR 3.5 
AMPHaS 2.5 Glu NH Glu Hy 4.0 
Glu HP 3.0 
Sta NH Sta OH 3.5 Glu Ha 3.5 
Glu Ha 2.5 BNA Ha 3.0 
Sta Hy 3.0 
Sta Ha Glu Hy Sta Ha 4.0 
Glu Hy :9 
Sta Hs 410 
Sta H/¶ 4.0 
Sta H6 3.0 Glu Ha Glu Hy 4.0 
Sta H6’ 4.0 Glu HP 4.0 
Sta HP 3.5 
Glu HP 3.5 
CPDHl7 
CPOHI I3 
CPOH236 
CPOH28 
CPOH329 
CPOH3I7 
CPOH424 
CPDH425 
CPOSI I3 
CPOSl35 
CPOSl47 
CPOS236 
cPos27 
CPGS29 
CPoS328 
CPOS333 
CPOS4 I5 
OS438 
CPGS444 
PREDICT ED 
N 
E 
N 
N 
N 
A 
N 
E 
N 
Y 
N 
Y 
ii 
N 
N 
N 
N 
Y -170 
Y -170 
Y -170 
Y -170 
Y 60 
N 60 
:: 2 
N -170 
N -120 
N -170 
:: -170 
y’ -170 6
N 60 
N 60 
N 60 
Y 60 
N - 
-I20 -160 
-120 -160 
-120 60 
-120 60 
-120 60 
-120 60 
-120 -160 
-120 -160 
-120 -160 
-120 -160 
-I20 -160 
-120 60 
-I20 60 
-120 60 
-120 60 
-120 60 
-120 -160 
-120 -160 
-120 -160 
’ Criteria for compatibility with NMR data: 
I, interproton distances c 5 A for all observed NOES; 
2, torsion angle values within 30° of lhe applied constraint for each 
@ angle; 
3, hydrogen bond involving the a NH of AMP and either the hydroxyl 
or the carbonyl oxygen of statinr; 
Y, meets criterion; 
N, does not meet criterion. 
U Approximate upper distance bounds were estimated by classifying 
crosspeak inlensity as strong, medium or wedk relative to the strong- 
est and weakest crosspcaks in the spectrum. 
of 64 possible combinations, Incorporating the hetero- 
nuclear coupling constants into the analysis reduced the 
total number of possible combinations to four, making 
their use as constraints in a distance geometry program 
tractable (see Table I and the following discussion). 
shifts are listed in Table I. Sixty-four interproton dis- 
tances were obtained from ROESY spectra and are 
listed in Table II. Approximate upper bound con- 
straints were determined based on the relative intensity 
of the ROESY crosspeak. Additional constraints were 
provided by three bond homonuclear and heteronuclear 
coupling constants. Portions of the I%- and 15N-edited 
TOCSY spectra are shown in Fig. 1. Analysis of the 
?JHF,Ha coupling constants alone, using published em- 
pirical relationships [43, gave four possible @ angles for 
the Leu, Sta and OIu residues. This resulted in a total 
The temperature dependence of the amide NH pro- 
tons (Table I) indicated that only the AMPMA o NH 
had a low temperature coefficient and was therefore a 
good candidate for involvement in hydrogen bonding 
[173. An NOE between the AMPMA cc NH and the a 
methylene protons of statine suggested that the best 
hydrogen bond acceptors were probably either the hy- 
droxyl oxygen or the carbonyl oxygen of statine. 
The torsion angle and NOE distance constraints from 
the NMR data were entered into the distance geometry 
program, DGEOM, to generate acceptable conforma- 
tions. Distance geometry runs were initiated with eight 
different sets of constraints. Each set had a hydrogen 
bond constraint between the a NH of AMPMA and 
Fig. I, Expansions of the ‘“C-edited (a and b) and lsN-edited (c and d) TOCSY spectw of 100 mM peptidomimetic in U.5 ml ofdimethylsuiioxided6 
at 298K. Shown arc selected NH, HB crosspeaks. Horizontal displacements of the indicated crosspeaks arise from lhe one bond Q-H@ or N-H 
coupling and vertical displacement corresponds to the three bond Nl+CB or l-@-N coupling. The pulse sequence used in this study is shown; see 
text for experimental details. 
101 
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Fig, 2. Stereo views of the (a) predicted and (b) experimental cyclic peptidomimetic conformations (heavy lines) in the renin binding pocket (light 
lines). The dotted line in (b) indicates a possible hydrogen bond. 
either the hydroxyl oxygen (cpoh series) or the carbonyl 
oxygen (cpos series) of statine and one of the four pos- 
sible combinations of the three constrained $ angles 
(designated 1 through 4). Fifty structures were obtained 
from each run. Using the program Compare [13], the 
rms fit of each of the fifty conformers to every other 
conformer was determined. Based on the rms fits, the 
conformations were classified into families of structures 
which differed by less than 1.0 A average RMSD (all 
atoms excluding the two methylenenapthyl groups) 
using a hierarchical cluster analysis [IS]. A total of 19 
families were found using this approach. 
A representative conformer for each of the 19 families 
was minimized using thirty-four maximal NOE distance 
constraints and three torsion constraints determined 
from the coupling constant analysis. The structure was 
then subjected to constrained molecular dynamics. In 
order to obtain an energetically reasonable structure, 
102 
one conformer extracted from the last 5 IX of each 
dynamics run was energy minimized without any con- 
straints. The constraint violations of these final struc- 
tures as well as the originally modeled conformation are 
listed in Table III. A structure was considered compat- 
ible with NMR results if it met all three criteria listed 
in Table III. 
Notably, the structure of the peptidomimetic pre- 
dicted in the design phase of the project does not meet 
any of the criteria listed above. Furthermore, none of 
the final structures from the cpoh series are consistent 
with the NOE data. Of the eleven structures minimized 
from the cpos series, two structures (cpos29 and 
cpos236) were compatible with the NMR data. Forty- 
seven of the SO total structures which resulted from the 
distance geometry starting set cpos2 were in families 
represented by these two structures. The average 
RMSD of the macrocyclic backbone heavy atoms be- 
Volume 302, number 1 FEBS LETTERS May 1992 
tween cpos29 and cpos236 is 0.35 A Stereoviews of the 
originally predicted conformation and the cpos29 struc- 
ture are shown in Fig. 2a and b, respectively. 
4. CONCLUSION 
A solution conformation derived from the above 
NMR and distance geometry analyses upports the for- 
mation of an internal hydrogen bond involving the 
AMPMA c1 NI-I and the carbonyl oxygen of statine. The 
phi angles predicted for this structure are -170 (Glu), 
-120 (Sta) and 60 (Leu), consistent with homo and 
heteronuclear coupling constants. In the model of the 
inhibitor-enzyme complex, the peptidomimetic binds to 
the enzyme with the Sta hydroxyl group located directly 
between the active site aspartic acid residues while the 
macrocyclic system extends out over the enzyme flap 
region (Fig. 2a). The occurrence of the hydrogen bond 
across the peptidomimetic ring in the two structures 
that satisfy the NMR constraint:i causes a significant 
conformationa! change relative to that predicted by the 
modeling studies, This apparently hinders the desired 
interactions in the renin active site. 
One explanation for the observed weak binding is 
that the molecule may transiently exist in the originally 
predicted bound conformation and there is a considera- 
ble free energy cost in achieving this conformation. It 
is thus demonstrated that inhibitor design based on the 
three dimensional structure of an enzyme warrants ad- 
ditional conformational studies of the uncomplexed in- 
hibitor. 
We have demonstrated the use of both “N- and I%- 
edited TOCSY to measure, at natural abundance, heter- 
onuclear three bond coupling constants that can greatly 
reduce the number of possible torsional angles that rev 
suit from homonuclear analysis alone. These con- 
straints are necessary supplements in these small, par- 
tially constrained systems where NOE information 
alone is not sufficient o define a structure. 
To gain additional insight into this system, we are 
currently pursuing crystallographic verification of the 
structure of the peptidomimetic bound to human renin 
and kinetic analysis of the binding. 
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